Circulation. 2003;108:1640-1645
Published online before print September 8, 2003, doi: 10.1161/01.CIR.0000087592.47401.37
Published online before print September 8, 2003, doi: 10.1161/01.CIR.0000087592.47401.37
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:1640.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells
From the Division of Pulmonary and Critical Care Medicine (T.N., L.T.V., J.L.F., G.Z., L.S., D.Q., P.N.K.) and the Departments of Pathology (G.J.B.) and Anesthesiology (G.B., R.G.P.), Stanford University Medical Center, Stanford, Calif.
Correspondence to Peter N. Kao, MD, PhD, Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA 94305-5236. E-mail peterkao{at}stanford.edu
Received January 16, 2003; de novo received April 3, 2003; revision received May 20, 2003; accepted May 21, 2003.
Background— Pulmonary vascular injury by toxins can induce neointimal formation, pulmonary arterial hypertension (PAH), right ventricular failure, and death. We showed previously that simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in pneumonectomized rats injected with the alkaloid toxin monocrotaline. The present study was undertaken to investigate the efficacy of simvastatin and its mechanism of reversing established neointimal vascular occlusion and pulmonary hypertension.
Methods and Results— Pneumonectomized rats injected with monocrotaline at 4 weeks demonstrated severe PAH at 11 weeks (mean pulmonary artery pressure [mPAP]=42 versus 17 mm Hg in normal rats) and death by 15 weeks. When rats with severe PAH received simvastatin (2 mg · kg-1 · d-1 by gavage) from week 11, there was 100% survival and reversal of PAH after 2 weeks (mPAP=36 mm Hg) and 6 weeks (mPAP=24 mm Hg) of therapy. Simvastatin treatment reduced right ventricular hypertrophy and reduced proliferation and increased apoptosis of pathological smooth muscle cells in the neointima and medial walls of pulmonary arteries. Longitudinal transcriptional profiling revealed that simvastatin downregulated the inflammatory genes fos, jun, and tumor necrosis factor-
and upregulated the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a.
Conclusions— Simvastatin reverses pulmonary arterial neointimal formation and PAH after toxic injury.
Key Words: statins • pulmonary heart disease • vasculature • remodeling
This article has been cited by other articles:
 |
|
 |
|
  E. D. Michelakis, M. R. Wilkins, and M. Rabinovitch Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension Circulation, September 30, 2008; 118(14): 1486 - 1495. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Perros, D. Montani, P. Dorfmuller, I. Durand-Gasselin, C. Tcherakian, J. Le Pavec, M. Mazmanian, E. Fadel, S. Mussot, O. Mercier, et al. Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 81 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Homma, T. Nagaoka, V. Karoor, M. Imamura, L. Taraseviciene-Stewart, L. A. Walker, K. A. Fagan, I. F. McMurtry, and M. Oka Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L71 - L78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takahashi, H. Nakamura, M. Seki, Y. Shiraishi, M. Yamamoto, M. Furuuchi, T. Nakajima, S. Tsujimura, T. Shirahata, M. Nakamura, et al. Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L882 - L890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kapoor, P. Varadarajan, and R. G. Pai Echocardiographic predictors of pulmonary hypertension in patients with severe aortic stenosis Eur J Echocardiogr, January 1, 2008; 9(1): 31 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lagna, M. M. Ku, P. H. Nguyen, N. A. Neuman, B. N. Davis, and A. Hata Control of Phenotypic Plasticity of Smooth Muscle Cells by Bone Morphogenetic Protein Signaling through the Myocardin-related Transcription Factors J. Biol. Chem., December 21, 2007; 282(51): 37244 - 37255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Keddissi, W. G. Younis, E. A. Chbeir, N. N. Daher, T. A. Dernaika, and G. T. Kinasewitz The Use of Statins and Lung Function in Current and Former Smokers Chest, December 1, 2007; 132(6): 1764 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Carlin, A. J. Peacock, and D. J. Welsh Fluvastatin Inhibits Hypoxic Proliferation and p38 MAPK Activity in Pulmonary Artery Fibroblasts Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 447 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. McMurtry, S. Bonnet, E. D. Michelakis, S. Bonnet, A. Haromy, and S. L. Archer Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L933 - L940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Patel, S. Zhang, F. Murray, R. Y. S. Suda, B. P. Head, U. Yokoyama, J. S. Swaney, I. R. Niesman, R. T. Schermuly, S. S. Pullamsetti, et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension FASEB J, September 1, 2007; 21(11): 2970 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Laudi, S. Trump, V. Schmitz, J. West, I. F. McMurtry, H. Mutlak, U. Christians, J. Weimann, U. Kaisers, and W. Steudel Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L630 - L638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. White, D. F. Meoli, R. F. Swarthout, D. Y. Kallop, I. I. Galaria, J. L. Harvey, C. M. Miller, B. C. Blaxall, C. M. Hall, R. A. Pierce, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L583 - L590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bauer, T. M. Moore, and I. F. McMurtry Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L580 - L582. [Full Text] [PDF]
|
|
|
|
|
|
M. Li, Y. Liu, P. Dutt, B. L. Fanburg, and D. Toksoz Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin Am J Physiol Lung Cell Mol Physiol, August 1, 2007; 293(2): L463 - L471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. J. Suzuki, H. Nagase, C. M. Wong, S. V. Kumar, V. Jain, A.-M. Park, and R. M. Day Regulation of Bcl-xL Expression in Lung Vascular Smooth Muscle Am. J. Respir. Cell Mol. Biol., June 1, 2007; 36(6): 678 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Girgis, S. Mozammel, H. C. Champion, D. Li, X. Peng, L. Shimoda, R. M. Tuder, R. A. Johns, and P. M. Hassoun Regression of chronic hypoxic pulmonary hypertension by simvastatin Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1105 - L1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Pai, N. Kapoor, R. C. Bansal, and P. Varadarajan Malignant Natural History of Asymptomatic Severe Aortic Stenosis: Benefit of Aortic Valve Replacement Ann. Thorac. Surg., December 1, 2006; 82(6): 2116 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Taraseviciene-Stewart, R. Scerbavicius, K.-H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper, and N. F. Voelkel Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L668 - L676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Said Mediators and modulators of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Distler and A. Pignone Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment Rheumatology, October 1, 2006; 45(suppl_4): iv22 - iv25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gurbanov and X. Shiliang The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 499 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Hothersall, C McSharry, and N C Thomson Potential therapeutic role for statins in respiratory disease. Thorax, August 1, 2006; 61(8): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper and L. J. Rubin Update in pulmonary hypertension 2005. Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 499 - 505. [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Michelakis Spatio-Temporal Diversity of Apoptosis Within the Vascular Wall in Pulmonary Arterial Hypertension: Heterogeneous BMP Signaling May Have Therapeutic Implications Circ. Res., February 3, 2006; 98(2): 172 - 175. [Full Text] [PDF]
|
|
|
|
|
|
Spoken sessions Thorax, December 1, 2005; 60(suppl_2): ii4 - ii52. [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Lee, D.-S. Lee, E.-K. Kim, K.-H. Choe, Y.-M. Oh, T.-S. Shim, S.-E. Kim, Y.-S. Lee, and S.-D. Lee Simvastatin Inhibits Cigarette Smoking-induced Emphysema and Pulmonary Hypertension in Rat Lungs Am. J. Respir. Crit. Care Med., October 15, 2005; 172(8): 987 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Kawut, E. M. Horn, K. K. Berekashvili, A. C. Widlitz, E. B. Rosenzweig, and R. J. Barst von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension Chest, October 1, 2005; 128(4): 2355 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Kao Simvastatin Treatment of Pulmonary Hypertension: An Observational Case Series Chest, April 1, 2005; 127(4): 1446 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. McMurtry, S. Bonnet, X. Wu, J. R.B. Dyck, A. Haromy, K. Hashimoto, and E. D. Michelakis Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis Circ. Res., October 15, 2004; 95(8): 830 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Newman, B. L. Fanburg, S. L. Archer, D. B. Badesch, R. J. Barst, J. G.N. Garcia, P. N. Kao, J. A. Knowles, J. E. Loyd, M. D. McGoon, et al. Pulmonary Arterial Hypertension: Future Directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases Workshop Circulation, June 22, 2004; 109(24): 2947 - 2952. [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin and N. Galie Pulmonary arterial hypertension: a look to the future J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 89S - 90S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Vaszar, T. Nishimura, J. D. Storey, G. Zhao, D. Qiu, J. L. Faul, R. G. Pearl, and P. N. Kao Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats Physiol Genomics, April 13, 2004; 17(2): 150 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Abe, H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, T. Hattori, Y. Nakashima, K. Kaibuchi, K. Sueishi, et al. Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats Circ. Res., February 20, 2004; 94(3): 385 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Robbins Advancing Therapy for Pulmonary Arterial Hypertension: Can Animal Models Help? Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 5 - 6. [Full Text] [PDF]
|
|